Bacteriological Study of Carbapenem and Aminoglycoside Resistance in Staphylococcus Aureus Recovered from Patient in Baghdad Province
Keywords:Staph.aureu, carbapenems, aminoglycosids
Background: In population- and hospital-acquired infections, Staphylococcus aureus is one of the most
powerful causative agents. Aminoglycosides are active bactericidal drugs and are frequently used to
treat staphylococcal infections in conjunction with beta-lactams or glycopeptides. Staphylococcus aureus
is immune to carbapenems and other beta-lactams A different mechanism that can lead to carbapenem
resistance is the active expulsion of carbapenems from the periplasmic space after their entry, due to the
high distribution of these bacteria that are now immune to other antibiotics, it has become more difficult to
treat these drug-resistant strains. Materials and Methods: A total of 130 staph.aureus isolates were isolated
from different clinical samples in some public & private hospitals in Baghdad city during the period from
November to December 2019. Bacterial identification was done using conventional cultural & chemical
methods & and VITEk 2 cards for identification (GP), while the minimum inhibitory concentration (MIC)
testing was performed using disk diffusion & (AST-GP30) cards in VITEK 2 automated system. Results:
By using disk duffusion test out of 130 of Staph.aureus isolate, 76(58.4%) were resistant to aminoglycosids
antibiotics (gentamicin) while 29(22.3%) were resistant to carbapenem antibiotics (imipenem) The MIC of
different antibiotics was performed on 26 isolates using (VITEK2AST-GP30) showed that 18(69.2%) were
resistant to aminoglycosids antibiotics (gentamicin) while 26(100%) were resistant to carbapenem antibiotics
(imipenem). Conclusion: The MIC of different antibiotics By using disk duffusion the Staph.aureus isolate
resistant to gentamicin 76(58.4%) and 29(22.3%) were resistant to imipenem, while, by VITEK2AST-GP30
showed 18(69.2%) were resistant to gentamicin , while 26(100% were resistant to imipenem.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Re use and mixing of content policy- We follow Creative Commons Licence Policy. We follow CC BY. Please refer below for all details
This license lets others distribute, remix, adapt, and build upon our work, even commercially, as long as they credit us for the original creation.
- The journal allows readers to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose.
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to retain publishing rights without restrictions